, Volume 175, Issue 1–2, pp 91–98 | Cite as

Pseudomembranous Candidiasis in HIV/AIDS Patients in Cali, Colombia

  • Luz Ángela Castro
  • María Inés ÁlvarezEmail author
  • Ernesto Martínez


Candida albicans is the most frequently isolated yeast from the oral cavity of HIV/AIDS individuals. The use of fluconazole has increased the number of resistant or less-sensitive Candida species different than C. albicans. The purpose of this study was to identify the Candida species producing pseudomembranous candidiasis in patients suffering from AIDS, their relationship with CD4+ counts and their sensitivity to fluconazole and itraconazole. We studied 71 patients at a hospital in the city of Cali. Samples of white plaque were seeded on CHROMagar Candida, yeast identification was done with API 20C Aux, and susceptibility testing was determined by E test. Ninety-three yeast isolates were obtained, 52 single and 41 mixed. C. albicans was the most isolated, followed by C. glabrata. An increased frequency of isolates and variety of Candida species occurred in patients with a CD4+ cell count ≤100 cells/mm3 without significant differences (p = 0.29). The susceptibility study showed that 8 (8.6 %) isolates were resistant to fluconazole and 11 (11.8 %) to itraconazole, while 6 (8.8 %) C. albicans were simultaneously resistant. No association was found between the isolates of C. albicans or Candida species different than C. albicans and the use of fluconazole (p = 0.21). The results of this study indicate that in the tested population, fluconazole continues to be the best treatment option for oropharyngeal candidiasis in patients suffering from AIDS (HIV/AIDS); however, susceptibility tests are necessary in patients who present therapeutic failure.


Oropharyngeal candidiasis Candidaalbicans Candida species different than C. albicans HIV CD4+ Lymphocytes Fluconazole 



This research was funded by the Universidad del Valle, project number CI 1584.


  1. 1.
    Pinzón EM, Bravo SM, Méndez F, Clavijo GM, León ME. Prevalencia y factores relacionados con la presencia de manifestaciones orales en pacientes con VIH/SIDA, Cali, Colombia. Colomb Med. 2008;39:346–55.Google Scholar
  2. 2.
    Aguirre-Urízar JM, Echebarría-Goicouría MA, Eguía-del-Valle A. Acquired immunodeficiency syndrome: manifestations in the oral cavity. Med Oral Patol Oral Cir Bucal. 2004;9(Suppl):153–7.PubMedGoogle Scholar
  3. 3.
    Giannini PJ, Shetty KV. Diagnosis and management of oral candidiasis. Otolaryngol Clin North Am. 2011;44:231–40.PubMedCrossRefGoogle Scholar
  4. 4.
    Holmes CB, Wood R, Badri M, Zilber S, Wang B, Maartens G, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr. 2006;42:464–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Egusa H, Soysa NS, Ellepola AN, Yatani H, Samaranayake LP. Oral candidosis in HIV-infected patients. Curr HIV Res. 2008;6:485–99.PubMedCrossRefGoogle Scholar
  6. 6.
    Redding SW. The role of yeasts other than Candida albicans in oropharyngeal candidiasis. Curr Opin Infect Dis. 2001;14:673–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Baradkar VP, Kumar S. Species identification of Candida isolates obtained from oral lesions of HIV infected patients. Indian J Dermatol. 2009;54:385–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Sant’Ana P, Milan EP, Martinez R, Queiroz-Telles F, Ferreira MS, Alcântara AP, et al. Multicenter Brazilian study of oral Candida species isolated from AIDS patients. Mem Inst Oswaldo Cruz. 2002;97:253–7.CrossRefGoogle Scholar
  9. 9.
    Nadagir SD, Chunchanur SK, Halesh LH, Yasmeen K, Chandrasekhar MR, Patil BS. Significance of isolation and drug susceptibility testing of non-Candida albicans species causing oropharyngeal candidiasis in HIV patients. Southeast Asian J TropMed Public Health. 2008;39:492–5.Google Scholar
  10. 10.
    Masiá Canuto M, Gutiérrez Rodero F, Ortiz de la Tabla Ducasse V, Hernández Aguado I, Martín González C, Sánchez Sevillano A, et al. Determinants for the development of oropharyngeal colonization or infection by fluconazole-resistant Candida strains in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 2000;19:593–601.Google Scholar
  11. 11.
    Walmsley S, King S, McGeer A, Ye Y, Richardson S. Oropharyngeal candidiasis in patients with human immunodeficiency virus: correlation of clinical outcome with in vitro resistance, serum azole levels, and immunosuppression. Clin Infect Dis. 2001;32:1554–61.PubMedCrossRefGoogle Scholar
  12. 12.
    Gutiérrez C, de Bedout C, Tobón AM, Cano LE, Arango M, Tabares AM, et al. Sensibilidad a fluconazol y voriconazol de aislamiento de Candida spp., obtenidos de aislamientos de mucosa oral de pacientes con sida. Infectio. 2007;11:183–9.Google Scholar
  13. 13.
    Mendoza N, Arora A, Motta A, Arias C. Prevalence of oral candidiasis in the HAART era in developing countries: A cohort from Colombia. J Am Acad Dermatol. 2008; 58 S2 AB94.Google Scholar
  14. 14.
    Hospenthal DR, Murray CK, Beckius ML, Green JA, Dooley DP. Persistence of pigment production by yeast isolates grown on CHROMagar Candida medium. J Clin Microbiol. 2002;40:4768–70.PubMedCrossRefGoogle Scholar
  15. 15.
    Álvarez MI, Suárez BL, Caicedo LD. Isolation of Candida dubliniensis for the first time in Cali, Colombia, and its identification with phenotyping methods. Mycopathologia. 2009;167:19–24.PubMedCrossRefGoogle Scholar
  16. 16.
    Gales AC, Pfaller MA, Houston AK, Joly S, Sullivan DJ, Coleman DC, et al. Identification of Candida dubliniensis based on temperature and utilization of xylose and α-methyl-D-glucoside as determined with the API 20C AUX and Vitek YBC systems. J Clin Microbiol. 1999;37:3804–8.PubMedGoogle Scholar
  17. 17.
    Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; 3rd Informational Supplement, M27–S3. Wayne PA: Clinical and Laboratory Standards Institute; 2008.Google Scholar
  18. 18.
    Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A. CLSI subcommittee for antifungal susceptibility testing. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat. 2010;13:180–95.PubMedCrossRefGoogle Scholar
  19. 19.
    Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN. Triazole and echinocandin MIC distributions with epidemiological cutoff values for differentiation of wild-type strains from non-wild-type strains of six uncommon species of Candida. J Clin Microbiol. 2011;49:3800–4.PubMedCrossRefGoogle Scholar
  20. 20.
    Pfaller MA, Espinel-Ingroff A, Canton E, Castanheira M, Cuenca-Estrella M, Diekema DJ, et al. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol. 2012;50:2040–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Mane A, Panchvalli S, Bembalkar S, Risbud A. Species distribution & antifungal susceptibility of oral Candida colonising or infecting HIV infected individuals. Indian J Med Res. 2010;131:836–8.PubMedGoogle Scholar
  22. 22.
    Schmidt-Westhausen AM, Bendick C, Reichart PA, Samaranayake LP. Oral candidosis and associated Candida species in HIV-infected Cambodians exposed to antimycotics. Mycoses. 2004;47:435–41.PubMedCrossRefGoogle Scholar
  23. 23.
    Maninder J, Usha A. Isolation, characterization and antifungal susceptibility pattern of Candida species causing oropharyngeal candidiasis in HIV positive patients. J Commun Dis. 2008;40:177–81.PubMedGoogle Scholar
  24. 24.
    Arora U, Jagdev M, Jindal N. Immunosuppression level in HIV-positive patients with oropharyngeal candidiasis. Indian J Med Microbiol. 2009;27:174–5.PubMedCrossRefGoogle Scholar
  25. 25.
    Magaldi S, Mata S, Hartung C, Verde G, Deibis L, Roldán Y, et al. In vitro susceptibility of 137 Candida sp. isolates from HIV positive patients to several antifungal drugs. Mycopathologia. 2001;149:63–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Gupta E, Vajpayee M, Xess I, Seth P. Oral candidiasis in HIV-infected patients and its relation to CD4 + counts: an adjunct clinical marker of HIV disease progression. Trop Doct. 2006;36:127.PubMedCrossRefGoogle Scholar
  27. 27.
    Pfaller MA, Woosley LN, Messer SA, Jones RN, Castanheira M. Significance of Molecular Identification and Antifungal Susceptibility of Clinically Significant Yeasts and Moulds in a Global Antifungal Surveillance Programme. Mycopathologia. 2012 May 13. [Epub ahead of print].Google Scholar
  28. 28.
    Loreto ES, Scheid LA, Nogueira CW, Zeni G, Santurio JM, Alves SH. Candida dubliniensis: epidemiology and phenotypic methods for identification. Mycopathologia. 2010;169:431–43.PubMedCrossRefGoogle Scholar
  29. 29.
    Delgado W, Aguirre JM. Las micosis orales en la era del sida. Rev Iberoam Micol. 1997;14:14–22.PubMedGoogle Scholar
  30. 30.
    Li L, Redding S, Dongari-Bagtzoglou A. Candida glabrata: an emerging oral opportunistic pathogen. J Dent Res. 2007;86:204–15.PubMedCrossRefGoogle Scholar
  31. 31.
    Redding SW, Kirkpatrick WR, Dib O, Fothergill AW, Rinaldi MG, Patterson TF. The epidemiology of non-albicans Candida in oropharyngeal candidiasis in HIV patients. Spec Care Dentist. 2000;20:178–81.PubMedCrossRefGoogle Scholar
  32. 32.
    Chai LY, Denning DW, Warn P. Candida tropicalis in human disease. Crit Rev Microbiol. 2010;36:282–98.PubMedCrossRefGoogle Scholar
  33. 33.
    Dronda F, Alonso-Sanz M, Laguna F, Chaves F, Martínez-Suárez JV, Rodríguez-Tudela JL, et al. Mixed oropharyngeal candidiasis due to Candida albicans and non-albicans Candida strains in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 1996;15:446–52.PubMedCrossRefGoogle Scholar
  34. 34.
    Redding SW, Dahiya MC, Kirkpatrick WR, Coco BJ, Patterson TF, Fothergill AW, et al. Candida glabrata is an emerging cause of oropharyngeal candidiasis in patients receiving radiation for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol. 2004;97:47–52.CrossRefGoogle Scholar
  35. 35.
    Bodhade AS, Ganvir SM, Hazarey VK. Oral manifestations of HIV infection and their correlation with CD4 count. J Oral Sci. 2011;53:203–11.PubMedCrossRefGoogle Scholar
  36. 36.
    Thompson GR, Patel PK, Kirkpatrick WR, Westbrook SD, Berg D, Erlandsen J, et al. Oropharyngeal candidiasis in the era of antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109:488–95.PubMedCrossRefGoogle Scholar
  37. 37.
    Hamza OJ, Matee MI, Moshi MJ, Simon EN, Mugusi F, Mikx FH, et al. Species distribution and in vitro antifungal susceptibility of oral yeast isolates from Tanzanian HIV-infected patients with primary and recurrent oropharyngeal candidiasis. BMC Microbiol. 2008;8:135.PubMedCrossRefGoogle Scholar
  38. 38.
    Barchiesi F, Colombo AL, McGough DA, Forhergill AW, Rinaldi MG. In vitro activity of itraconazole against fluconazole-susceptible and—resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob Agents Chemother. 1994;38:1530–3.PubMedCrossRefGoogle Scholar
  39. 39.
    Kothavade RJ, Kura MM, Valand AG, Panthaki MH. Candida tropicalis: its prevalence, pathogenicity and increasing resistance to fluconazole. J Med Microbiol. 2010;59:873–80.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  • Luz Ángela Castro
    • 1
  • María Inés Álvarez
    • 2
    Email author
  • Ernesto Martínez
    • 3
  1. 1.School of Bacteriology and Clinical LaboratoryUniversidad del ValleCaliColombia
  2. 2.Department of MicrobiologyUniversidad del ValleCaliColombia
  3. 3.Department of Internal Medicine, Universidad del ValleUniversity Hospital of ValleCaliColombia

Personalised recommendations